Smith Kline & French Laboratories Limited

Smithkline Beecham Corporation

Rodney C Young

Graham J Durant

Charon R Ganellin

Michael L Roantree

Geoffrey R Owen

Mythily Vimal

Roderick Alan Porter

John Kitteringham

Gary Thomas Borrett

Mark R Shipton

Alberto J Kaumann

Francis D King

Thomas H Brown

Laramie Mary Gaster

Zev Tashma

Martin Jones

David G Cooper

Peter D Miles

Ian R Smith

Robert C Mitchell

Lawrence I Kruse

Paul Adrian Wyman

Keith Raymond Mulholland

Gareth J Sanger

Guy Anthony Kennett

Kay A Wardle

Gordon S Baxter

Ann J Hunter

Zeav Tashma

Lars M Wood

A (+) or (-) enantiomer of a compound of formula (I) wherein R.sup.4 is methyl or ethyl, or a salt, solvate, or hydtrate thereof, processes for preparing said compounds and pharmaceutical compostions containing them. Compounds of formula (+) are 5-HT.sub.1 -like agonists.

Enantiomer of carbazole derivative as 5-HT1-like agonists

A (+) or (-) enantiomer of a compound of formula (I) wherein R.sup.4 is methyl or ethyl, or a salt, solvate or hydrate thereof, processes for preparing said compounds and pharmaceutical compositions containing them. Compounds of formula (+) are 5-HT.sub.1 -like agonists. ##STR1##

Process for preparing enantiomers of carbazole derivatives as 5-HT.sub.1

Use of a compound of general formula (I): ##STR1## wherein R.sup.1 represents hydrogen, halogen, trifluoromethyl, nitro, hydroxy, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, arylC.sub.1-6 alkoxy, --CO.sub.2 R.sup.4, --(CH.sub.2).sub.n CN, --(CH.sub.2).sub.n CONR.sup.5 R.sup.6, --(CH.sub.2).sub.n SO.sub.2 NR.sup.5 R.sup.6, C.sub.1-6 alkanoylamino(CH.sub.2).sub.n, or C.sub.1-6 alkylsulphonylamino(CH.sub.2).sub.n ;

Medicaments 1,2,3,4-tetrahydrocarbazoles and 5-HT.sub.1 agonist use

##STR1## A (+) or (-) enantiomer of a compound of formula (I) wherein R.sup.4 is methyl or ethyl, or a salt, solvate or hydrate thereof, processes for preparing said compounds and pharmaceutical compositions containing them. Compounds of formula (+) are 5-HT.sub.1 -like agonists.

Enantiomers of carbazole derivatives as 5-HT.sub. 1-like agonists

Use of a compound of general formula (I): ##STR1## wherein: R.sup.1 represents hydrogen, halogen, trifluoromethyl, nitro, hydroxy, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, arylC.sub.1-6 alkoxy, --CO.sub.2 R.sup.4, --(CH.sub.2).sub.n CN, --(CH.sub.2).sub.n CONR.sup.5 R.sup.6, --(CH.sub.2).sub.n SO.sub.2 NR.sup.5 R.sup.6, C.sub.1-6 alkanoylamino (CH.sub.2).sub.n, or C.sub.1-6 alkylsulphonylamino (CH.sub.2).sub.n ;

Medicaments

Process for preparing an enantiomer of a carbazole derivative

Process of preparing enantiomers of carbazole derivatives

A (+)or (-) enantiomer of a compound of formula (I) wherein R.sup.4 is methyl or ethyl, or a salt, solvate or hydrate thereof, processes for preparing said compounds and pharmaceutical compositions containing them. Compounds of formula (+) are 5-HT.sub.1 -like agonists.

Enantiomers of carbazole derivatives as 5-HT.sub.1 -like agonists

Tryptamine analogues, their synthesis and their use as 5-HT.sub.1 -like

5-HT.sub.4 receptor antagonists

##STR1## Use of a compound of general formula (I), wherein R.sup.1 represents hydrogen, halogen, trifluoromethyl, nitro, hydroxy, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, arylC.sub.1-6 alkoxy, --CO.sub.2 R.sup.4, --(CH.sub.2).sub.n CN, --(CH.sub.2).sub.n CONR.sup.5 R.sup.6, --(CH.sub.2).sub.n SO.sub.2 NR.sup.5 R.sup.6, C.sub.1-6 alkanoylamino(CH.sub.2).sub.n, or C.sub.1-6 alkylsulphonylamino(CH.sub.2).sub.n ; R.sup.4 represents hydrogen, C.sub.1-6 alkyl or arylC.sub.1-6 alkyl; R.sup.5 and R.sup.6 each independently represent hydrogen or C.sub.1-6 alkyl, or R.sup.5 and R.sup.6 together with the nitrogen atom to which they are attached form a ring; n represents 0, 1 or 2; and R.sup.2 and R.sup.3 each independently represent hydrogen, C.sub.1-6 alkyl; or benzyl or together with the nitrogen atom to which they are attached form a pyrrolidino, piperidino or hexahydroazepino ring; or a physiologically acceptable salt thereof, in the manufacture of a medicament for the treatment of a condition where a 5-HT.sub.1 -like agonist is indicated, for example migraine. Novel compounds of formula (I), processes for preparing them and pharmaceutical compositions containing them are also described.

Use of tetrahydrocarbazone derivatives as 5HT.sub.1 receptor agonists

This invention relates to aminoalkylphenoxyalkyl substituted heterocycles. These compounds antagonize the action of histamine on histamine H.sub.2 -receptors in the brain. A compound of the invention is 2-[3-[3-(piperidinomethyl)phenoxy]propylamino]benzthiazole.

Pyridine compounds

The disclosure relates to a class of 2-(pyridylalkylamino)-3-hydroxypyridines which are active as histamine H.sub.1 -antagonists.

3-hydroxypyridines

Growing community of inventors

Bengeo, United Kingdom

Rodney C Young